Insider · CIK 0001646396
Steffen Thomas
Files at AVXL (ANAVEX LIFE SCIENCES CORP.). First filing -, latest -.
In brief
Steffen Thomas files SEC Form 4 as director at AVXL (ANAVEX LIFE SCIENCES CORP.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Steffen Thomas has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 4 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 5, 2025 | AVXL ANAVEX LIFE SCIENCES CORP. | MOption exercise Common stock | +50,000 | $1.76 | $88k | 55,000 | Jun 9, 2025 |
| Jun 5, 2025 | AVXL ANAVEX LIFE SCIENCES CORP. | FTax withholding Common stock | -11,349 | $7.75 | $88k | 43,651 | Jun 9, 2025 |
| Jun 5, 2025 | AVXL ANAVEX LIFE SCIENCES CORP. | MOption exercise Stock Option (Right to Buy)derivative | -50,000 | $0.00 | $0 | 0 | Jun 9, 2025 |
| Mar 31, 2025 | AVXL ANAVEX LIFE SCIENCES CORP. | AGrant or award Stock Option (Right to Buy)derivative | +50,000 | $0.00 | $0 | 50,000 | Apr 2, 2025 |
Questions about Steffen Thomas
Answered from the filings on this page, as of the latest one.
Is Steffen Thomas buying or selling?
Steffen Thomas has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Steffen Thomas's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Steffen Thomas has 0.
Where does Steffen Thomas file Form 4?
Steffen Thomas has filed Form 4 at AVXL (ANAVEX LIFE SCIENCES CORP.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.